Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uvisun is a multi-vitamin dietary supplement developed and marketed by MTI Medical. It contains a high-potency combination of fat-soluble vitamins: Vitamin A (8000 IU), Vitamin D3 (8000 IU), and Vitamin E (20 mg). The product is designed to address or prevent nutritional deficiencies. Vitamin A (retinol) is critical for maintaining healthy vision, skin, and immune function by acting through retinoic acid receptors. Vitamin D3 (cholecalciferol) is essential for calcium absorption and bone mineralization via the vitamin D receptor. Vitamin E (alpha-tocopherol) serves as a lipid-soluble antioxidant that protects cell membranes from oxidative damage. Uvisun is available as softgel capsules for oral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitamin A + vitamin D3 + vitamin E.